AutoImmune Myloral PLA for MS planned for late 1997, CEO tells UBS.
Executive Summary
AUTOIMMUNE MYLORAL PLA FOR MS TO BE FILED IN FOURTH QUARTER 1997 assuming positive results from Phase III trials to be completed in May, AutoImmune CEO Robert Bishop, PhD, told analysts at the UBS Securities Life Sciences Conference in New York City Oct. 7. Myloral is an "oral solid dosage formulation of purified myelin from bovine brains," Autoimmune said. The company is seeking an indication for treatment of relapsing/remitting multiple sclerosis.